Last reviewed · How we verify
NCT05433337: PROSPER-FM-EXT
Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management: An Extension Study
NA trial testing Digital ACT in Fibromyalgia in 60 participants. Completed in 5 March 2024.
5 March 2024
Quick facts
| Lead sponsor | Swing Therapeutics, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 8 June 2022 |
| Primary completion | 5 March 2024 |
| Estimated completion | 5 March 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Digital ACT
Conditions studied
- Fibromyalgia — all drugs for Fibromyalgia →
Sponsor
Swing Therapeutics, Inc.
Who can join
Adults 22 to 75, any sex, with Fibromyalgia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is designed as a 9-month extension of the original study (PROSPER-FM). The purpose of the extension study is to assess the long-term (up to 1 year) response to a digital therapy in the treatment of fibromyalgia.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05433337
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Digital ACT
Trials testing the same drug.
- NCT05243511 — Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management · Phase 3 · completed
- NCT05149222 — "REACT-FM-EXT": Real-World Evidence From Smartphone-Based Acceptance and Commitment Therapy in Fibromyalgia: An Extensio · NA · completed
- NCT05011162 — "REACT-FM" Real-World Evidence From Smartphone-Based Acceptance and Commitment Therapy in Fibromyalgia · NA · completed
- NCT05005351 — "SMART-FM": Smart-Phone Based Digital Therapeutic for Management of Fibromyalgia · Phase 2 · completed
Other recruiting trials for Fibromyalgia
Currently open trials in the same condition.
- NCT02285868 — ATI Evidence-based Guide Investigating Clinical Services · active not recruiting
- NCT07245303 — Neural Mechanisms of Light Driven Analgesia · NA · recruiting
- NCT05901259 — The EXOPULSE Study - a Database for Routine Follow-up of Clinical Outcomes · recruiting
- NCT07358754 — The Relationship Between Serum S100B and Brain-Derived Neurotrophic Factor · recruiting
- NCT07465991 — The Effect of Digital Cognitive Behavioural Therapy for Insomnia on Physical Activity in Fibromyalgia · NA · recruiting
Other Swing Therapeutics, Inc. trials
Trials by the same sponsor.
- NCT05243511 — Prospective Study to Evaluate a Digital Regimen for Fibromyalgia Management · Phase 3 · completed
- NCT05149222 — "REACT-FM-EXT": Real-World Evidence From Smartphone-Based Acceptance and Commitment Therapy in Fibromyalgia: An Extensio · NA · completed
- NCT05011162 — "REACT-FM" Real-World Evidence From Smartphone-Based Acceptance and Commitment Therapy in Fibromyalgia · NA · completed
- NCT05005351 — "SMART-FM": Smart-Phone Based Digital Therapeutic for Management of Fibromyalgia · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05433337 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Swing Therapeutics, Inc.
- Last refreshed: 27 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05433337.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing